Keyword: Rubius Therapeutics
Gilead's clinical director joins Nimbus to lead discovery; Immunocore’s CMO jumps to Tmunity; Kite taps Eisai vet to lead CAR-T sales.
The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the Flagship Pioneering startup races to get into the clinic.
Venture capital firm Flagship Pioneering has got a major $618 million in capital, the biggest in its 17-year history, topping its total to $2.3 billion.
Allergan CFO Hilado and Gilead COO Young will retire from their positions and Rubius has poached a GSK SVP as CMO.
Carpenter will work as point person on Rubius’ development activities as it gears up to move its CAR-T-rivaling cell therapy into human testing.
Rubius is developing off-the-shelf red-cell therapeutics its president Torben Straight Nissen thinks will be “an improved and superior cellular therapy over the CAR-Ts.” Buoyed by a $120 million round, the Flagship Pioneering-backed biotech is working on a pipeline that extends beyond cancer.
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. Here are this year's standouts.
Epstein was named executive chairman of Rubius; ex-PTC exec Rothera jumped ship to Orchard; Maverick tapped former Pacira COO Scibetta as CEO.
Rubius Therapeutics has raised $120 million to take two of its off-the-shelf red blood cell therapies into the clinic.